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A b s t r a c t
Introduction: Pregnant women  negative for human platelet antigen 1a 
(HPA-1a) are at risk of alloimmunization with fetal HPA-1a antigen inherited 
from the father, and their offspring may develop fetal and neonatal alloim-
mune thrombocytopenia (FNAIT). The aim of this study was to analyze the 
frequency of HPA-1a alloimmunization in pregnant Polish women, the fea-
sibility of using maternal platelets for intrauterine transfusions in women 
subjected to diagnostic fetal blood sampling (FBS) and to discuss potential 
consequences of alloimmunization.
Material and methods: Fifteen thousand two hundred and four pregnant 
women were typed for HPA-1a; HPA-1a negative were screened for anti-
HPA-1a. Alloimmunized women received specialist perinatology care; some 
of them were subjected to FBS, followed by transfusion of HPA-1a negative 
platelet concentrates (PC) prepared from maternal blood.
Results: Three hundred seventy-three (2.5%) women were HPA-1a negative, 
and 32 (8.6%) tested positively for anti-HPA-1a. Antibodies were detected 
in 22 women during pregnancy. Diagnostic FBS followed by PC transfusion 
was performed in 14 woman, who were platelet donors for their 16 unborn 
babies. Blood donations were tolerated well by the patients, and also intra-
uterine platelet transfusions were uneventful. Pharmacotherapy with intra-
venous immunoglobulins was implemented in 11/22 patients.
Conclusions: HPA-1a negative women (ca. 2.5% of all pregnant patients) are 
at risk of alloimmunization with HPA-1a antigen and developing FNAIT. Allo-
immunized women can be donors of platelets for their offspring providing 
removal of antibodies from PC. Owing to potential complications, special 
care should be taken if an alloimmunized woman was qualified as a blood 
or stem cell recipient.
Key words: HPA-1a cohort study, anti-human platelet antigen 1a antibodies, 
fetal/neonatal alloimmune thrombocytopenia, platelet transfusions.
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Introduction
Antibodies to platelet antigens developed 
during pregnancy or after platelet transfusion/
stem cell transplantation may be responsible for 
fetal/neonatal alloimmune thrombocytopenia 
(FNAIT); furthermore, they may exert unfavorable 
effects in patients subjected to transfusions and 
transplantations. Potential presence of anti-plate-
let antibodies should also be considered in wom-
en qualified as blood donors. 
Fetal/neonatal alloimmune thrombocytopenia 
is diagnosed in 1 per 1000–2000 live newborns 
[1–5]. The disease is caused by destruction of fetal 
or newborn platelets by maternal alloantibodies 
against fetal human platelet antigen (HPA). Alloge-
neic antibodies do not destroy maternal platelets 
but may contribute to fetal/neonatal thrombocy-
topenia or even intrauterine death. In ca. 10% of 
the cases, presence of antibodies may result in in-
tracranial hemorrhages, half of them occurring al-
ready in utero [1–7]. In Caucasians, FNAIT usually 
results from HPA-1a antigen incompatibility (85% 
of cases) [1, 3, 4, 8]; a  woman without HPA-1a 
antigens (HPA-1a negative – HPA-1b/b genotype) 
synthesizes antibodies against these antigens of 
her fetus, inherited from the father.
Each year, ca. 30 pregnant women are referred 
to the Institute of Hematology and Transfusion 
Medicine (IHTM) in Warsaw due to suspected 
FNAIT. However, the evidence from prospective 
studies suggests that the incidence of this dis-
ease in Poland approximates 1 per 2000 live-born 
children [8, 9], and consequently, FNAIT should be 
expected in 200 newborns annually [8]. Fetal/neo-
natal alloimmune thrombocytopenia is usually not 
detected until birth, when the newborn presents 
with typical signs of thrombocytopenia or intra-
cranial hemorrhage. Consequently, general prac-
titioners, obstetricians, hematologists and other 
specialists who consult pregnant women should 
be aware of the potential consequences of allo-
immunization.
To prevent FNAIT and to increase the awareness 
of this disease among patients and physicians, we 
have introduced a screening program “Prevention 
of fetal/neonatal alloimmune thrombocytopenia 
(FNAIT) in Polish newborns” (PREVFNAIT). Within 
the framework of the project, we screen pregnant 
women for presence of HPA-1a antigen to iden-
tify the pregnancies at risk. The project was un-
dertaken by the IHTM in cooperation with UiT The 
Arctic University of Norway, Tromso (Norway) and 
the Second Department of Obstetrics and Gyne-
cology, Medical Center for Postgraduate Education 
in Warsaw, within the framework of a diagnostic 
grant supported from Norwegian funds. Women in 
whom HPA-1a antibodies were detected received 
specialist perinatal care. Whenever necessary, 
platelet concentrates (PCs) for intrauterine/neo-
natal transfusions were prepared at the Depart-
ment of Transfusion Medicine (IHTM).
The aim of this study was to analyze the fre-
quency of HPA-1a alloimmunization among Pol-
ish pregnant women and the possibility of using 
maternal platelets for fetal/neonatal transfusions. 
Moreover, we discuss potential consequences of 
presence of anti-platelet antibodies for subse-
quent pregnancies and for women qualified as 
blood donors and recipients. Such information is 
of utmost importance for all medical specialists, 
especially if a  HPA-1a negative woman requires 
blood transfusion or stem cell transplantation. 
Material and methods
Patients
Human platelet antigen 1a typing was per-
formed in 15 204 pregnant women at 8–28 weeks 
of gestation (gw) within the framework of the 
PREVFNAIT Project (the list of collection sites can 
be found at http://www.konfliktplytkowy.ihit.waw.
pl). The protocol of the study was approved by the 
Local Bioethics Committee at the IHTM, and writ-
ten informed consent was sought from all preg-
nant women prior to enrollment.
HPA-1a typing
For the purpose of the screening tests, 4–5 ml 
of EDTA anti-coagulated blood were collected from 
each woman. HPA-1a antigen typing was per-
formed by means of flow cytometry (FACS) [10] 
or real-time polymerase chain reaction (PCR) [11]. 
In women in whom no HPA-1a antigens were de-
tected by FACS, as well as in HPA-1b/b genotype 
carriers, another blood sample, collected during 
a  subsequent visit, was retested with an alter-
native method. High-capacity protocols for both 
methods enabled us to examine samples from 
300 Polish collection sites for the presence of HPA-
1a antigen. The samples delivered to the IHTM 
within 7 days of collection were tested by flow 
cytometry; those delivered later (after day 7) were 
examined by the genetic method. Each patient re-
ceived a written report with the screening results. 
HPA-1a negative women were informed about po-
tential risks related to alloimmunization with fetal 
HPA-1a, including fetal/neonatal thrombocytope-
nia in current and subsequent pregnancies, and 
post-transfusion/post-transplantation complica-
tions in recipients of blood/stem cell products.
Anti-HPA-1a antibody analysis
HPA-1a negative women were screened for anti- 
HPA-1a anti-platelet antibodies at 16–20, 28, 32 
and 40 gw, as well as 6 weeks after delivery. Blood 
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samples for antibody screening were delivered to 
the IHTM within 24 h from collection. Antibodies 
were detected with the aid of the Monoclonal An-
tibody Immobilization of Platelet Antigens (MAIPA) 
test with monoclonal antibodies against the 
platelet glycoprotein GPIIbIIIa receptor (anti-CD41, 
clone P2, Beckman Coulter) [12].
Clinical follow-up
Women with anti-HPA-1a antibodies were sub-
jected to regular ultrasound examination and 11 of 
them were treated with intravenous immunoglob-
ulins (IVIG); (treatment outcomes will be the sub-
ject of a separate analysis). Diagnostic fetal blood 
sampling (FBS; cordocentesis) was performed 
in 14 out of 22 anti-HPA-1a immunized women. 
All the therapeutic procedures were approved by 
the Local Bioethics Committee at the Center of 
Medical Postgraduate Education in Warsaw. In all 
the cases, FBS was followed by the transfusion 
of compatible maternal platelets to prevent pro-
longed bleeding from the umbilical vein. Maternal 
blood was collected one day before the planned 
intrauterine procedure and platelet concentrate 
(PC) for intrauterine transfusion was prepared.
Preparation of PCs for intrauterine 
transfusions
To qualify for whole blood donation, pregnant 
woman should meet the following criteria: satis-
factory blood count, good overall clinical status 
and lack of viral markers.
The unit of whole blood was separated by cen-
trifugation to obtain red blood cell concentrate 
(RBC) and platelet rich plasma (PRP) (J-M/E; Beck-
man centrifuge). After centrifugation, PRP was 
transferred to one of the empty bags of a quadru-
ple set and filtered within a closed system (TSCD; 
Terumo) to remove leukocytes. Leukoreduced PRP 
was again centrifuged to obtain PC (J-M/E; Beck-
man centrifuge). The bag was placed in a mechan-
ical press and the platelet poor plasma (PPP) was 
transferred to an empty bag with 50 ml of plasma 
left above the platelet pellet. The platelet pellet 
was left in a platelet mixer (Poll) until the follow-
ing day. In order to remove maternal plasma, ca. 
50 ml of 0.9% NaCl was added and centrifuged. 
The procedure was performed within a closed sys-
tem. After removal of the maternal plasma and 
saline mixture, the platelet pellet was resuspend-
ed in 10–20 ml of 5% albumin solution (depend-
ing on the required target volume of the compo-
nent). The bag with PC was suspended in albumin 
solution, rested for about 10 min at 20–24°C and 
placed in a platelet mixer. Once homologous, the 
PC was irradiated to prevent transfusion associat-
ed graft versus host diseases (TA-GvHD) (Nordion; 
Canada). Two samples were drawn for serological 
and quality control and then PCs were issued for 
immediate transfusion. 
As the fetal platelet count was unknown prior 
to cordocentesis, the whole PC volume was initial-
ly not transfused. Only small volumes of maternal 
PC (up to 8 ml) were administered to secure local 
hemostasis following the umbilical vein puncture. 
Then the needle was withdrawn from the umbili-
cal vein and the puncture site was observed while 
the blood sample was analyzed. If no prolonged 
bleeding was observed after cordocentesis and/or 
the level of platelets was not extremely low (when-
ever placental cord insertion had been punctured, 
fetal bleeding was not visible), the procedure was 
completed. 
Results
Outcomes of the screening, as well as negative 
results of testing for HPA-1a, are summarized in 
Table I. A total of 373/15 204 women were found 
to be HPA-1a negative (HPA-1bb). The frequency 
of HPA-1a negative phenotype, which determines 
the risk for alloimmunization against fetal HPA-1a 
antigens and FNAIT, was estimated at 2.5% of our 
series. This proportion is similar to that found in 
another Polish study in which HPA-1a antigen was 
detected by means of ELISA [9]. In one woman, the 
results of genetic and serological screening were 
inconclusive: no HPA-1a antigen was detected on 
her platelets and she was identified as an HPA-
1a/b genotype carrier. This patient was eventually 
diagnosed with thrombocytopenia. A discrepancy 
between an HPA-1a negative result and presence 
of HPA-1a/b genotype was probably due to a poly-
Table I. Screening outcomes in all pregnant women subjected to the study, and test results for HPA-1a negative 
women
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morphism of the ITGB3 gene encoding the GPIIIa 
glycoprotein. Sequencing of the ITGB3 gene re-
gion with an SNP polymorphism that determines 
HPA-1a/-1b antigens excluded the presence of 
mutations at linking sites of starters and probes 
used in real-time PCR (data not shown). The lack 
of HPA-1a antigen expression was most likely 
linked to presence of a mutation in the flanking 
gene region. Sequencing of the whole ITGB3 gene 
is still ongoing.
Anti-HPA-1a antibodies were detected in 32 
out of 373 HPA-1a negative women who were re-
ferred for repeated sampling. Anti-HPA-1a was de-
tected in 32 women, either in pregnancy (n = 22) 
or thereafter (n = 10). The frequency of anti-HPA-
1a antibody detection in our series approximated 
8.6% and was slightly lower than previously re-
ported [13].
Women who tested positively for anti-HPA-1a 
gave birth to a  total of 34 newborns (2 patients 
were in twin pregnancies).
Women at high risk of FNAIT (i.e. with FNAIT 
diagnosed in the older sibling) were treated phar-
macologically with IVIG to prevent the recurrence 
of this condition in current pregnancy. Such phar-
macotherapy was implemented in 11 out of the 
22 immunized pregnant women identified within 
the framework of PREVFNAIT (Table I). 
We decided to perform FBS to diagnose fetal 
thrombocytopenia in 14 immunized women from 
our series. The subset of immunized women in-
cluded both nulliparas in whom antibodies were 
detected in early pregnancy and multiparas who 
tested positively for the antibodies during the 
first screening visit but had no history of FNAIT 
in past pregnancies. This procedure was followed 
in every case by intrauterine transfusion of ma-
ternal platelets to the fetus to prevent fetal ex-
sanguination (Table II). All pregnant women qual-
ified for platelet donation were in good general 
status and tested negatively for viral markers. 
Blood donation procedures were tolerated well 
by pregnant women irrespective of pregnancy 
stage. The volume of prepared PCs ranged from 
14 ml to 25 ml (mean: 20.4 ±2.8 ml), with a plate-
let count of 0.22 to 0.92 × 1011 per PC unit (mean: 
0.50 × 1011/unit).
A total of 16 fetal blood sampling procedures 
were performed in 14 fetuses (more than one 
procedure was required in 2 patients) to diag-
nose thrombocytopenia and/or to assess the ef-
ficacy of IVIG treatment with respect to the mode 
of delivery (cesarean section or vaginal birth). 
Both cordocentesis and PC transfusions were 
uneventful in all 16 cases. Fetal thrombocytope-
nia was diagnosed in 7 cases, including 3 fetuses 
with very low platelet counts (below 50 × 103/ml). 
Neither prolonged bleeding nor other complica-
tions were observed after the platelet transfusion 
procedure. Fetal blood sampling and PC transfu-
sion were also planned in another woman with 
twin pregnancy at 34 gw, but the procedure was 
eventually not performed due to fetal bradycar-
dia during a cordocentesis attempt. The patient 
delivered via cesarean; both premature neonates 
were born in good condition and are developing 
normally. 
In 8 cases, diagnostic cordocentesis was per-
formed between 25 and 28 weeks of gestation. 
The FNAIT was diagnosed in 3 cases, and IVIG was 
implemented in these patients. As no thrombocy-
topenia was found in another 5 cases, they were 
managed conservatively.
Another 8 cordocenteses were performed be-
tween 33 and 36 gw. Thrombocytopenia was de-
tected in 4 cases, suggesting that previous treat-
ment was inefficient. Consequently, corticosteroid 
therapy was additionally implemented in these 
Table II. History of cordocenteses in alloimmunized women (N = 22)
No cordocentesis Cordocenteses: 14 fetuses/16 procedures 









































*In two fetuses cordocentesis was performed twice: at 25–28 weeks (thrombocytopenia diagnosed and treatment introduced) and at 
33–36 weeks of gestation (thrombocytopenia diagnosed and additional treatment introduced).
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patients. Four patients were qualified for vaginal 
delivery based on the FBS results. 
Discussion
Women with alloantibodies against HPA-1a 
antigen are at increased risk for repeated FNAIT 
and consequently in future pregnancies should 
be referred to a specialist medical center capable 
of providing them with adequate care and moni-
toring. Alloantibodies may be synthesized by any 
woman, including by patients presenting with 
thrombocytopenia of other etiology (thrombocy-
topenia in pregnancy, idiopathic thrombocytope-
nic purpura). Our series included two pregnant 
women with mild thrombocytopenia of unknown 
etiology, which was probably gestational thrombo-
cytopenia.
While presence of alloantibodies against fetal 
platelet antigens does not result in thrombocy-
topenia, it may lead to post-transfusion compli-
cations in alloimmunized women who received 
blood or stem cells [14]. Therefore, alloimmuni-
zation by platelet antigens should raise interest 
of not only obstetricians but also general practi-
tioners, hematologists and other specialists who 
provide blood transfusions. 
Alloimmunized women subjected to blood 
transfusion are at increased risk for post-trans-
fusion purpura (PTP). In persons who presented 
with a  normal platelet count before transfusion, 
this rare albeit severe type of post-transfusion 
bleeding disorder typically manifests approxi-
mately 5–10 days after the procedure. Post-trans-
fusion purpura is usually observed after red blood 
cell transfusions, and its incidence rate is esti-
mated at 1/50,000 transfusions [15–17]. Women 
with anti-HPA antibodies are also at risk for other 
complications, such as refractoriness to platelet 
transfusions or post-transfusion febrile reaction 
[18, 19]. Moreover, they may experience pro-
longed thrombocytopenia or engraftment failure 
following transplantation of hematopoietic stem 
cells [20].
Therapeutic decisions in patients with suspect-
ed FNAIT were made primarily on the basis of the 
obstetric history of a given patient and in select-
ed cases on the results of blood sampling; at our 
center still no conclusive data regarding maternal 
antibody level and fetal thrombocytopenia are 
available. Until now direct fetal blood sampling is 
the only option to detect fetal thrombocytopenia. 
As an invasive procedure, fetal blood testing may 
pose a  risk for complications, such as bleeding 
from the umbilical vessels, fetal bradycardia, pre-
mature rupture of membranes and infection that 
can lead to prompt delivery of a premature fetus 
or even intrauterine fetal death. According to the 
literature, the risk of fetal loss due to cordocen-
tesis approximates 1–2% per procedure, but may 
increase in cases of FNAIT [21–23]. Thrombocyto-
penic fetuses are at increased risk of prolonged 
bleeding from the umbilical vein after the veni-
puncture. This risk can be mitigated, however, if 
an immediate intrauterine transfusion of HPA-1bb 
platelets is performed before removing the needle 
from the vessel. At our center, we used maternal 
platelet concentrates in which plasma with anti-
bodies was replaced with albumin solution. Such 
PCs are commonly recommended for transfusion 
in fetuses and newborns with FNAIT [24–26]. 
A total of 14 women included in our series were 
subjected to cordocentesis and PC transfusion. 
No prolonged bleeding from the puncture site has 
been observed. This implies that PC transfusion 
may prevent bleeding complications and does not 
pose a risk for any noticeable adverse fetal reac-
tions. It should be stressed, however, that as op-
posed to Rh disease, intrauterine platelet transfu-
sions (IUTs) are not recommended as the first-line 
treatment of FNAIT. This precaution stems mainly 
from the short half-life of transfused platelets and 
resultant increased risk for fetal bleeding during 
repeated procedures, as well as from a  signifi-
cant risk of pregnancy loss, possible boosting of 
HPA-1a-immunization and additional alloimmuni-
zation. Consequently, the use of IUTs should be 
restricted to selected clinical cases. Minimizing 
the number of fetal sampling procedures is also 
commonly recommended, and these procedures 
have even been abandoned in some countries 
[27]. However, FBS provides accurate data on fe-
tal platelet count and guides further treatment. 
We did not implement any specific treatment in 
5 immunized women from our series in whom 
fetal thrombocytopenia was suspected but not 
eventually confirmed on FBS. In another 3 cases, 
in which primary treatment turned out to be inef-
ficient, FBS enabled us to modify the therapeutic 
protocol prior to delivery. Owing to a considerable 
cost of high-dose IVIG therapy, FBS may represent 
a diagnostic option in suspected fetal thrombocy-
topenia. However, the procedure should be per-
formed only in selected cases, at clinical centers 
experienced in fetal therapy. Although FBS was 
shown to be safe, it should be emphasized that 
this evidence originates from studies in which fe-
tal blood samples were collected by highly skilled 
persons [28].
Still no international consensus has been 
reached with regards to prevention of FNAIT con-
sequences [29–34]. Most commonly, including 
at our center, immunized mothers at high risk of 
FNAIT are treated with high doses of IVIG (typical-
ly, 1 g/kg/week), with or without corticosteroids. 
In some countries, this treatment is followed by 
cesarean section 2–4 weeks before term, with 
compatible platelets secured for the neonate. 
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However, the treatment of FNAIT is outside the 
scope of this paper and as such will be discussed 
in our future publications. 
In conclusion, all pregnant women regardless 
of their platelet count are at risk of FNAIT. HPA-1a 
negative women are at risk for FNAIT in future preg-
nancies, and therefore should be screened for anti-
HPA-1a antibodies and referred to specialized tertia-
ry obstetrics centers. HPA-1a negative women with 
anti-HPA-1a antibodies can be donors of platelets 
for their own children/fetuses. In Poland, but not 
in Norway, they can be also blood/platelet donors 
for patients with anti-HPA-1a antibodies, providing 
that blood components for transfusion have been 
deprived of plasma with antibodies. Transfusion of 
platelets in HPA-1a negative women may be com-
plicated due to the presence of anti-HPA antibodies. 
Such patients should receive “antigen-negative” 
(HPA-1a negative) blood components to reduce the 
risk for post-transfusion thrombocytopenic purpura, 
refractoriness to platelet transfusions or post-trans-
fusion febrile reactions.
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